Celldex Therapeutics Inc (CLDX.OQ)
Fri, Jun 16 2017
* Celldex Therapeutics announces additions to the board of directors and senior management team
* Celldex presents promising overall survival data from phase 2 study of single-agent glembatumumab vedotin in patients with checkpoint-refractory metastatic melanoma
* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:
BRIEF-COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 5.1 PCT PASSIVE STAKE IN CELLDEX THERAPEUTICS AS OF DEC 31, 2016
* COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS A 5.1 PERCENT PASSIVE STAKE IN CELLDEX THERAPEUTICS INC AS OF DEC 31, 2016 - SEC FILING Source text (http://bit.ly/2lwtvZF) Further company coverage:
* Files for offering of up to 18.4 million shares of common stock by the selling stockholders Source text : (http://bit.ly/2kpoaTY) Further company coverage:
- Celldex: Can It Succeed Just Once?
- Celldex Therapeutics: Nobody Expects The Spanish Inquisition
- Celldex: Where Does This Small Biotech Stock Go From Here?
- Celldex Therapeutics' (CLDX) CEO Anthony Marucci on Q4 2016 Results - Earnings Call Transcript
- Celldex Therapeutics, Inc 2016 Q4 - Results - Earnings Call Slides
- Immunotherapy Bearish Overreaction Can Create Opportunity